Custom mRNA vaccine aims to stop liver cancer recurrence after surgery
NCT ID NCT07495215
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized mRNA vaccine (iNeo-Vac-R01) made from each patient's tumor, combined with an immunotherapy drug (PD-1 inhibitor), to prevent liver cancer from coming back after surgery. About 20 adults with early-stage liver cancer will receive the treatment. The goal is to see if it is safe and can extend the time without cancer returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital
RECRUITINGHangzhou, Zhejiang, 310016, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?